Plus: PE's law firm takeover is underway, who's paying Trump's H-1B fee & more
June 14, 2026  |  Log in   |  Read online   |  Manage your subscription  
PitchBook, a Morningstar company
The Weekend Pitch
Presented by Intapp
Sponsored by Intapp
Weekend Analysis
Stacking up SpaceX’s biggest winners
rosie-headshot.jpg
By Rosie Bradbury
Senior Venture Capital Reporter
As the dust settles on the $75B IPO, here’s how the SpaceX returns work out—and what to watch for next.
GRAPHIC SPACEX-FINAL

Stephanie Zhu/PitchBook

After 24 years as a private company, SpaceX became publicly traded on Friday. By the end of its first day, its stock price had settled at $160.95, bringing the company’s market capitalization to $2.11 trillion, between that of Amazon ($2.5 trillion) and Broadcom ($1.8 trillion).

At SpaceX’s IPO price of $135, Elon Musk‘s stake was worth approximately $866 billion. By the end of trading on Friday, the value of his stake jumped to $1.03 trillion.

Musk is, by far, the biggest beneficiary of the listing, making him the first trillionaire. And as the majority shareholder of SpaceX, Musk will continue to control more than 80% of the voting power.

Fund-returner? Try firm-returner

Some of Musk’s friends and early bettors on SpaceX are also teed up for massive gains. The paper value of Valor Equity Partners’ stake, whose managing partner, Antonio Gracias, is a close confidant of Musk and helped him develop the initial idea for SpaceX, was valued at $81 billion at market close on Friday.

To put Valor’s gains into perspective, between SpaceX’s founding and 2021, Valor invested between $400 million and $500 million into the company, according to a trial testimony Gracias gave in 2021. Even without accounting for investments that Valor may have made since 2021, the firm is sitting on paper returns of a more than 100x multiple on invested capital. Moreover, Gracias also has significant personal holdings in SpaceX.

Founders Fund, the venture capital firm of close Musk ally Peter Thiel, is also set for major returns: at a $135 share price, its stake is worth over $50 billion. DFJ Growth, the late-stage arm of the firm formerly known as Draper Fisher Jurvetson, invested $800 million across multiple rounds, taking a more than 2% stake.

Sequoia, which first invested in 2019, has a stake worth more than $20 billion, and even Andreessen Horowitz, which led SpaceX’s Series K in early 2023, still holds a roughly $10 billion stake at a $135 share price, per Bloomberg. Investors in Cursor, which SpaceX is expected to acquire later this year, also benefit from the windfall: Thrive Capital, a major backer of Cursor and a direct investor in SpaceX, has a stake worth roughly $10 billion.

For many investors, the SpaceX IPO is more than a liquidity event. Take Gracias: his firm’s stake is currently valued at more than the $59.3 billion in total assets under management that Valor Equity Partners reported this year.

Read more
A MESSAGE FROM INTAPP
Unlock value across the deal lifecycle with AI built for private capital

Your private capital firm probably has an AI strategy. But has it scaled AI successfully?

FTI Consulting research indicates that firms get the greatest value from AI when it’s applied consistently across the deal lifecycle — yet only 7% of firms have scaled AI enterprise-wide.

To unlock maximum value, firms need to move beyond generic point tools and turn to scalable platforms with Firm AI: AI that’s agentic, governed, and built for the complex relationships and workflows that define private capital.

Download our e-book to discover how Firm AI is reshaping competition — and how to scale it firmwide.

Intapp Column Image

TRIVIA

In other stock market listing news, Parabilis Medicines broke the record for the largest VC-backed biotech IPO earlier last week, raising around $670 million, just weeks after Kailera Therapeutics set the record. Parabilis develops an engineered peptide drug designed to treat cancerous tumors. Peptides are having a big moment in pharma. One of the world’s best-selling drugs is a peptide. Which one?

A) Aspirin
B) Eliquis
C) Penicillin
D) Ozempic


ICYMI

A selection from our most-read articles of the past few days.

  • Big Law is building its own AI, and suddenly Harvey and Legora’s billion-dollar valuations look a lot harder to justify. Learn more

  • Private equity is finally cracking open the law firm, as it deployed a record $5.1bn into legal services last year. The buy-and-build playbook that reshaped accounting is warming up.